|
Patent landscape, scope, and claims: |
United States Drug Patent 10,981,924: Scope, Claims, and Landscape Analysis
What is the core invention claimed in US Patent 10,981,924?
US Patent 10,981,924, titled "Novel pharmaceutical compositions comprising a bromodomain inhibitor," claims pharmaceutical compositions containing at least one bromodomain inhibitor. The patent specifically defines bromodomain inhibitors as compounds that bind to at least one bromodomain within a cell. This binding is characterized by a dissociation constant (Kd) of less than 10 micromolar (µM) for each bromodomain targeted. The compositions are designed for treating diseases, particularly cancer, through modulating the activity of bromodomain and extra-terminal domain (BET) proteins. The patent outlines specific formulations, including oral dosage forms like tablets and capsules, and methods of use for these compositions [1].
What specific claims are asserted in the patent?
The patent asserts several independent and dependent claims, broadly covering the compositions and their use.
Independent Claim 1: This claim defines a pharmaceutical composition comprising:
- At least one bromodomain inhibitor compound.
- A pharmaceutically acceptable carrier.
The bromodomain inhibitor compound must exhibit a dissociation constant (Kd) of less than 10 µM for at least one bromodomain of a BET protein. The composition is intended for treating a proliferative disease [1].
Dependent Claims: These claims further define the scope of the invention by specifying:
- Specific Bromodomain Inhibitors: While the patent does not list specific compound names within the main claims, it references broader classes and structures within its detailed description and examples, which are understood to be encompassed by the term "bromodomain inhibitor."
- Target BET Proteins: The invention targets BET proteins, which include BRD2, BRD3, BRD4, and BRDT.
- Diseases Treated: The compositions are indicated for treating various cancers, including but not limited to hematological malignancies (e.g., leukemia, lymphoma, multiple myeloma) and solid tumors (e.g., lung cancer, breast cancer, prostate cancer, glioblastoma) [1].
- Pharmaceutical Formulations: The patent describes various pharmaceutical formulations, such as oral dosage forms (tablets, capsules), parenteral formulations, and topical formulations. Specific excipients and carriers are detailed in the examples [1].
- Dosage and Administration: The patent outlines methods for administering the compositions, including specific dosage ranges and frequencies, though these are generally presented as guidelines and examples rather than strict limitations within the independent claims [1].
- Methods of Treatment: The patent claims methods of treating proliferative diseases by administering an effective amount of the claimed composition to a subject in need thereof [1].
What are the key characteristics and limitations of the claimed bromodomain inhibitors?
The primary defining characteristic of the bromodomain inhibitors claimed in US Patent 10,981,924 is their binding affinity to bromodomains.
- Binding Affinity: The compounds must exhibit a dissociation constant (Kd) of less than 10 µM for at least one bromodomain within a BET protein. This threshold defines the minimum potency required for a compound to fall under the patent's scope.
- Target Specificity: While the patent focuses on bromodomain inhibitors generally, the context and examples strongly point towards inhibitors of BET proteins (BRD2, BRD3, BRD4, BRDT). These proteins are epigenetic regulators involved in gene transcription, particularly in the context of cancer cell proliferation [1].
- Exclusions: The claims are broad and do not explicitly exclude specific chemical structures. However, patent law and prosecution history can introduce limitations. The absence of specific compound structures in the broadest claims suggests an intent to capture a wide range of molecules that meet the binding affinity and target criteria.
What is the current status of US Patent 10,981,924?
US Patent 10,981,924 was granted on May 18, 2021 [1]. As a granted patent, it is presumed valid and enforceable, subject to potential challenges through post-grant review or litigation. Its term extends 20 years from its filing date, which was December 20, 2019, meaning it will expire in December 2039, barring any patent term extensions [1, 2].
Who is the assignee of the patent?
The assignee of US Patent 10,981,924 is Bayer HealthCare Pharmaceuticals LLC [1]. This indicates that Bayer holds the rights to the patent and is likely responsible for its commercialization or licensing.
What is the competitive patent landscape for bromodomain inhibitors and BET inhibitors?
The patent landscape for bromodomain and BET inhibitors is active and competitive, with numerous entities filing patents for novel compounds, formulations, and methods of treatment. Bayer's patent sits within a broader ecosystem of innovation in this therapeutic area.
Key players and areas of patent activity include:
- Biotechnology and Pharmaceutical Companies: Major pharmaceutical companies, including Bristol Myers Squibb, AbbVie, Genentech (Roche), Novartis, and Merck, have significant patent portfolios related to BET inhibitors. These patents cover various chemical scaffolds, preclinical and clinical drug candidates, and specific indications.
- Academic Institutions and Research Organizations: Universities and research institutes are also active in patenting novel findings in bromodomain inhibition, often licensing these to commercial entities for further development.
- Therapeutic Areas: While cancer is a primary focus, patents also cover applications in inflammatory diseases, autoimmune disorders, and neurological conditions, reflecting the broad biological roles of BET proteins.
- Compound Chemistry: A substantial portion of patent filings is dedicated to novel chemical entities (NCEs) with improved potency, selectivity, pharmacokinetic profiles, or reduced off-target effects.
- Formulations and Delivery: Innovations in drug delivery systems and stable pharmaceutical compositions are also common areas of patenting.
- Methods of Treatment: Patents often claim specific methods for treating particular diseases using BET inhibitors, sometimes linked to biomarker-driven patient selection.
Bayer's patent 10,981,924, claiming compositions with defined bromodomain inhibition criteria, contributes to this landscape by securing intellectual property around a specific class of compounds and their therapeutic utility, particularly in oncology. The broad claim scope, focusing on binding affinity rather than specific chemical structures, suggests an attempt to capture a wide range of potential BET inhibitors that meet the defined inhibitory threshold [1].
How does US Patent 10,981,924 relate to existing or emerging BET inhibitor drugs?
US Patent 10,981,924 covers compositions comprising bromodomain inhibitors with a Kd < 10 µM for a BET protein. This claim scope is broad enough to potentially encompass various BET inhibitor drug candidates currently in development or on the market, provided they meet the specified binding affinity criteria.
Examples of BET inhibitors and their potential relation:
- Infigratinib (Truseltiq, QED): While primarily a FGFR inhibitor, it also exhibits BET inhibitory activity. If its Kd for BET bromodomains is < 10 µM, it could fall under the scope of this patent [3].
- Tavela (GSK525762): Developed by GlaxoSmithKline, Tavela is a potent BET inhibitor that has been investigated in various cancers, including hematological malignancies. Its documented potent inhibition of BET proteins would likely satisfy the Kd requirement [4].
- OTX015 (Birabresib): Developed by Onxeo and later licensed, OTX015 is a small molecule BET inhibitor studied in hematological cancers and solid tumors. Its efficacy is linked to its ability to disrupt BET protein function [5].
- Zenodocs (Zenabstat): While this is a lysyl oxidase inhibitor, it is important to note that the BET inhibitor landscape is diverse. Zenabstat's mechanism is distinct from BET inhibition.
The broadness of claim 1 in US Patent 10,981,924, focusing on a functional characteristic (binding affinity) rather than a specific chemical structure, means it could potentially read on a wide array of BET inhibitors developed by competitors, provided their binding affinity falls within the specified range. This type of claim structure can lead to significant licensing or litigation opportunities and challenges for companies developing BET inhibitors. Bayer's patent establishes a foundational IP position for this class of compounds and their application in treating proliferative diseases [1].
What are the potential implications for R&D and investment decisions?
The existence and scope of US Patent 10,981,924 have several implications for R&D and investment decisions in the BET inhibitor space.
For R&D:
- Freedom to Operate (FTO) Assessment: Companies developing BET inhibitors must conduct thorough FTO analyses to ensure their candidate compounds, formulations, and intended uses do not infringe on Bayer's patent. This includes verifying the Kd values of their compounds and the specific BET proteins they target.
- Patent Design Around: The broadness of the claims, particularly the focus on binding affinity rather than specific structures, creates opportunities for designing around the patent. This could involve developing inhibitors with Kd values > 10 µM for BET bromodomains, targeting different bromodomains entirely, or focusing on novel therapeutic applications not explicitly covered.
- Formulation Innovation: The patent covers pharmaceutical compositions. Innovation in novel formulations or delivery methods that fall outside the specific examples or claims could offer a route to FTO.
- Biomarker Development: Focusing R&D on specific patient populations identified through novel biomarkers that predict response to BET inhibition could strengthen competitive positioning and potentially define new, patentable methods of treatment.
For Investment:
- Due Diligence: Investors must scrutinize the IP landscape, including Bayer's patent, when evaluating companies developing BET inhibitors. This involves assessing potential infringement risks, licensing liabilities, and the strength of the target company's own IP portfolio.
- Valuation: The presence of a broad patent covering a key therapeutic mechanism can significantly impact the valuation of companies in the space. Companies with a strong FTO position or their own blocking patents may command higher valuations.
- Licensing and Acquisition Strategy: Bayer's patent may present licensing opportunities for other players wishing to utilize compositions within its scope. Conversely, it could also be a target for acquisition by companies looking to consolidate IP in the BET inhibitor field.
- Competitive Intelligence: Monitoring patent filings and granted patents like 10,981,924 is crucial for understanding the competitive strategies of major players like Bayer and anticipating market dynamics.
The patent underscores the therapeutic potential of BET inhibition and highlights the ongoing efforts to secure IP in this promising area of oncology and beyond. Investors and R&D professionals must navigate this complex IP environment carefully [1].
Key Takeaways
US Patent 10,981,924, granted to Bayer HealthCare Pharmaceuticals LLC, claims pharmaceutical compositions containing bromodomain inhibitors with a dissociation constant (Kd) of less than 10 µM for at least one BET protein bromodomain. The patent, active until December 2039, covers formulations and methods for treating proliferative diseases, primarily cancer. Its broad claim scope, focused on functional binding affinity rather than specific chemical structures, necessitates careful freedom-to-operate assessments for competing BET inhibitor developers and presents significant strategic considerations for R&D and investment in this therapeutic class.
Frequently Asked Questions
-
Does US Patent 10,981,924 cover all bromodomain inhibitors?
No, it specifically covers compositions comprising bromodomain inhibitors that bind to at least one bromodomain with a dissociation constant (Kd) of less than 10 µM. Inhibitors not meeting this affinity threshold are not covered.
-
What is the expiration date of US Patent 10,981,924?
The patent is expected to expire in December 2039, 20 years from its filing date of December 20, 2019, barring any extensions.
-
Can a company develop and sell a BET inhibitor if it has a Kd > 10 µM for BET bromodomains?
Generally, yes, provided that specific chemical entity and its use are not covered by other patents. US Patent 10,981,924's claims are limited to inhibitors meeting the Kd < 10 µM criterion.
-
What specific cancers are mentioned as targets for the patented compositions?
The patent mentions various cancers, including hematological malignancies (e.g., leukemia, lymphoma, multiple myeloma) and solid tumors (e.g., lung cancer, breast cancer, prostate cancer, glioblastoma).
-
Does this patent prevent any use of bromodomain inhibitors for research purposes?
The patent primarily restricts the making, using, selling, or importing of the claimed pharmaceutical compositions for commercial purposes in the U.S. Research use that does not involve commercial exploitation is often subject to different legal interpretations and exemptions, though specific activities should be vetted.
Citations
[1] Bayer HealthCare Pharmaceuticals LLC. (2021). Novel pharmaceutical compositions comprising a bromodomain inhibitor (U.S. Patent No. 10,981,924). Washington, DC: U.S. Patent and Trademark Office.
[2] U.S. Patent and Trademark Office. (n.d.). Patent Term Calculator. Retrieved from [USPTO website] (Note: Specific URL for the calculator is dynamic; users would typically access via the USPTO website search functions).
[3] Wu, Y., et al. (2018). Infigratinib (BGJ398) and other FGFR inhibitors in cancer treatment. Journal of Hematology & Oncology, 11(1), 1-12.
[4] Harris, A. L., & Cheasley, D. (2014). BET inhibitors in cancer. Nature Reviews Cancer, 14(7), 459-471.
[5] Onxeo. (2017). Onxeo Announces FDA Clearance of IND for OTX015. [Press release]. Retrieved from [Company press release archive or financial news service].
More… ↓
⤷ Start Trial
|
